2017
P3.02c-046 Safety, Clinical Activity and Biomarker Results from a Phase Ib Study of Erlotinib plus Atezolizumab in Advanced NSCLC Topic: IT
Rudin C, Cervantes A, Dowlati A, Besse B, Ma B, Costa D, Schmid P, Heist R, Villaflor V, Sarkar I, Huseni M, Foster P, O'Hear C, Gettinger S. P3.02c-046 Safety, Clinical Activity and Biomarker Results from a Phase Ib Study of Erlotinib plus Atezolizumab in Advanced NSCLC Topic: IT. Journal Of Thoracic Oncology 2017, 12: s1302-s1303. DOI: 10.1016/j.jtho.2016.11.1841.Peer-Reviewed Original Research
2016
441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC
Ma B, Rudin C, Cervantes A, Dowlati A, Costa D, Schmid P, Heist R, Villaflor V, Sarkar I, Huseni M, Foster P, O’Hear C, Gettinger S, Besse B. 441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC. Annals Of Oncology 2016, 27: ix141. DOI: 10.1016/s0923-7534(21)00599-8.Peer-Reviewed Original Research441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC
Ma B, Rudin C, Cervantes A, Dowlati A, Costa D, Schmid P, Heist R, Villaflor V, Sarkar I, Huseni M, Foster P, O'Hear C, Gettinger S, Besse B. 441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC. Annals Of Oncology 2016, 27 DOI: 10.1093/annonc/mdw594.005.Peer-Reviewed Original Research
2014
Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC) Metastatic Non-Small Cell Lung Cancer
Gettinger S, Chow L, Borghaei H, Shen Y, Harbison C, Chen A, Rizvi N. Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC) Metastatic Non-Small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s34-s35. DOI: 10.1016/j.ijrobp.2014.08.210.Peer-Reviewed Original ResearchA multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC).
Neal J, Wakelee H, Feliciano J, Goldberg S, Morgensztern D, Das M, Heist R, Lennes I, Muzikansky A, Edelman M, Gettinger S, Sequist L. A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2014, 32: 8088-8088. DOI: 10.1200/jco.2014.32.15_suppl.8088.Peer-Reviewed Original ResearchSafety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC.
Rizvi N, Chow L, Borghaei H, Shen Y, Harbison C, Alaparthy S, Chen A, Gettinger S. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. Journal Of Clinical Oncology 2014, 32: 8022-8022. DOI: 10.1200/jco.2014.32.15_suppl.8022.Peer-Reviewed Original ResearchReduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer
de Bruin EC, Cowell C, Warne PH, Jiang M, Saunders RE, Melnick MA, Gettinger S, Walther Z, Wurtz A, Heynen GJ, Heideman DA, Gómez-Román J, García-Castaño A, Gong Y, Ladanyi M, Varmus H, Bernards R, Smit EF, Politi K, Downward J. Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer. Cancer Discovery 2014, 4: 606-619. PMID: 24535670, PMCID: PMC4011693, DOI: 10.1158/2159-8290.cd-13-0741.Peer-Reviewed Original ResearchConceptsLung cancerMAP-ERK kinase (MEK) inhibitorsEGF receptorEGFR-mutant lung adenocarcinomaKinase inhibitorsHuman lung cancer cell linesResistance of lungSubgroup of patientsLung cancer cell linesCancer cell linesClinical responsivenessCombination therapyEGFR-TKIEGFR mutationsErlotinib resistanceLung adenocarcinomaRAS-ERK signalingEGFR inhibitionMEK inhibitorsErlotinibReduced expressionNF1 expressionPatientsCell linesNeurofibromin levels
2011
Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer (NSCLC).
Stinchcombe T, Socinski M, Moore D, Gettinger S, Decker R, Petty W, Blackstock A, Schwartz G, Lankford S, Morris D. Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2011, 29: 7016-7016. DOI: 10.1200/jco.2011.29.15_suppl.7016.Peer-Reviewed Original Research
2010
A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC).
Wakelee H, Gettinger S, Engelman J, Janne P, West H, Subramaniam D, Leach J, Wax M, Yaron Y, Lara P. A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2010, 28: 3017-3017. DOI: 10.1200/jco.2010.28.15_suppl.3017.Peer-Reviewed Original Research